alog_pcfb {MBNMAdose}

Studies of alogliptin for lowering blood glucose concentration in patients with type II diabetes

Description

A dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing different doses of alogliptin with placebo (Langford et al. 2016). The systematic review was simply performed and was intended to provide data to illustrate a statistical methodology rather than for clinical inference. Alogliptin is a treatment aimed at reducing blood glucose concentration in type II diabetes. The outcome is continuous, and aggregate data responses correspond to the mean change in HbA1c from baseline to follow-up in studies of at least 12 weeks follow-up. The dataset includes 14 Randomised-Controlled Trials (RCTs), comparing 5 different doses of alogliptin with placebo, leading to 6 different treatments (combination of dose and agent) within the network.

Usage

alog_pcfb

Format

A data frame in long format (one row per arm and study), with 46 rows and 6 variables:

• studyID Study identifiers

• agent Character data indicating the agent to which participants were randomised

• dose Numeric data indicating the standardised dose received

• y Numeric data indicating the mean change from baseline in blood glucose concentration (mg/dL) in a study arm

• se Numeric data indicating the standard error for the mean change from baseline in blood glucose concentration (mg/dL) in a study arm

• n Numeric data indicating the number of participants randomised

Details

alog_pcfb is a data frame in long format (one row per arm and study), with the variables studyID, agent, dose, y, se, and N.

References

Langford O, Aronson JK, van Valkenhoef G, Stevens RJ (2016). “Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.” Stat Methods Med Res. ISSN 1477-0334 (Electronic) 0962-2802 (Linking), doi:10.1177/0962280216637093.